agil highlight weak pull guidanc
page full analyst note apr
busi strategi outlook
spin-out hewlett packard divestitur
electron measur busi
novemb agil focus primarili provid tool
analyz structur properti variou chemic molecul
cell agil one lead provid chromatographi
mass spectrometri tool applic varieti
end market includ healthcar chemic energi food
environment field healthcare-rel applic
market agil gener half
sale
servic
instrument informat relev custom
chromatographi column sampl prepar tool
account rest agil sale half agil sale
recur natur howev even instrument sale rel
sticki end instrument life cycl especi
highli regul pharmaceut end market
agil sale applic intens
time-consum train requir master scientif
analysi agil aim increas exposur sticki
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research apr
estim dec
price data apr
rate updat apr
currenc amount express
busi strategi outlook
methodolog valu compani
overal think top-tier posit end market innov
market oper on-going cost control help
agil grow revenu midsingl digit compound annual
boost margin overal five-year forecast period
intern growth opportun look solid acquisit activ
continu boost growth prospect well profit
perspect expect agil return margin expans
rest forecast period chines
sale govern initi surround countri food
infrastructur gener pharmaceut price
constrain demand oper margin fiscal
origin spun hewlett-packard agil evolv
lead life scienc diagnost firm today agil measur
technolog serv broad base custom three oper
segment life scienc appli tool fiscal sale cross
lab sale consist consum servic relat life
scienc appli tool diagnost genom
half sale gener biopharmaceut chemic
energi end market also support clinic lab environment
forens food academ government-rel organ
compani geograph divers oper
china repres largest countri concentr
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
agil highlight weak pull guidanc
wide-moat agil announc preliminari result
second quarter low end previou
expect pull guidanc rest year
crisi compani expect
give detail chang late may
report full quarterli result although expect cut
expect given weak end-market dynam
anticip chang fair valu estim
point share remain overvalu opinion
gener suspect demand agil tool could
remain weak given econom impact on-going shelter-
in-plac order specif quarter agil
report core revenu growth came around
low end previou guidanc
agil gave detail around result manag
note sale fell significantli end march
custom restrict access close facil outright
chang work pattern agil client could
hurt recur non-recurring revenu stream
split roughli evenli agil
uncertainti around long mani custom
shutter oper agil pull guidanc
rest fiscal previous manag expect
revenu billion core growth
adjust earn per share
growth estim
manag tendenc give conserv guidanc
even cut expect significantli think
fair valu estim remain roughli appropri also
compani balanc sheet appear strong even
recent biotek acquisit end januari net
leverag stood time cash cover current
debt come due next year nearli time
boost fair valu estim agil
per share primarili reflect recent gener
impli multipl
top line incorpor annual growth
next five year includ acquisit activ add
nearli basi point organ growth prospect
end market expect agil organ growth led
biopharmaceut overal growth expect
double-digit biologic-rel growth consid robust
gener demand trend low-single-digit growth small
molecul expect low- mid-single-digit growth rate
agil appli market assumpt
consid agil rel lower price power
intermedi term eventu may affect
weaker econom environ certain appli market
well budget constraint academ govern
bottom line expect adjust earn per share
rise roughli compound annual next
five year sale growth primarili margin
expans share repurchas activ retreat
slightli base case scenario assum
oper margin rise expect
cost control effort continu potenti improv
margin primarili control sg line also
expect share repurchas activ account
basi point agil annual earn growth
discount assumpt weight averag
cost capit around
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
annual top-lin growth oper margin
drop mid-teen rise
slightli higher agil margin
scenario assum increas price pressur market
share loss competit addit overal
slowdown end market even includ
grow compound annual next five
year scenario use base-cas earn
assumpt agil valu time project earn
bear-cas scenario
instrument busi consist primarili chromatographi
ga liquid mass spectrometri test tool
intellectu properti on-going innov creat
intang asset moat sourc regulatori
reproduc factor contribut switch cost end
user moat sourc crucial agil on-going
target market
advantag agil enjoy strong return invest
capit includ goodwil roughli doubl capit cost
calcul
agil offer differenti technolog protect
variou intang asset includ patent copyright
trademark portfolio intellectu properti
innov prowess chosen field keep competitor
technolog sinc even slightli
differenti technic featur caus end user
prefer one tool anoth similar tool agil precis
scientif end market see intang asset around
differenti technolog signific moat sourc
differenti proprieti agil tool affect
perform accuraci speed variou research
project enabl differenti product featur
creat intang asset inform decis use
tool specif applic particularli begin
give agil medium uncertainti rate thank
sticki end market result rel steadi
demand trend despit depend one-tim
instrument sale delay weak time
gener economi specif end market
bull-cas scenario result per share fair valu
estim assum greater-than-anticip uptak
firm new product signific price power
quick rebound china scenario expect sale
growth compound annual
base-cas scenario oper margin rise
bull-cas scenario versu
base-cas scenario think adjust earn per
share grow compound annual
next five year includ share repurchas account
basi point growth rate use
base-cas earn assumpt agil valu
time project earn bull-cas scenario
bear-cas scenario result fair valu
estim model incorpor roughli
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
project order remain relev scientist earli
project phase agil must continu innov
abil innov contribut intang asset
busi well agil signific incent
innov sinc new product contribut posit mix
benefit although enjoy like-for-lik price power
gener
initi choic tool base primarili intang
asset agil benefit substanti switch cost
end market exampl agil
develop
manufactur biopharmaceut
extrem sticki busi end market agil
analyt tool critic compon product
method variou drug specifi directli
molecul regulatori approv applic regul
requir product method throughout drug
life-cycle chang manufactur process
includ qualiti assur qualiti control test
often perform agil tool would requir approv
regul regulatori requir reproduc
concern includ employe train learn curv
creat switch cost biopharmaceut custom
result long potenti benefit period
agil highli regul market brand small
molecul period last year discoveri
patent expir larg molecul biolog
period last even longer due difficult
manufactur process also drug key patent
expir gener manufactur often seek util
product method use brand
manufactur reduc product variabl
adopt gener manufactur creat even
longer benefit period agil specif molecul
see narrow still strong moat around agil
analyt instrument use less regul
research applic repres nearli half
agil sale -- intang asset switch
cost support agil moat end market
well importantli agil lead market ga
chromatographi tool often use less
regul end market agil gener doubl
revenu closest peer ga chromatographi
product believ differenti technolog
strong reput innov capabl creat
intang asset advantag ga chromatographi
long use life around year long
life contribut sustain econom profit
even outsid highli regul biopharmaceut end
market specif custom use tool
agil gener recur consum servic
revenu also believ switch cost persist
due train workflow product concern end
user highli special applic scientist
technician travel learn curv new
instrument test reproduc consist may
suffer end user probabl would need signific
technolog improv induc switch provid
end tool use life overal think intang
asset switch cost advantag associ
highli special analyt instrument creat
stabl market share agil enjoy even
agil diagnost divis repres
sale also advantag intang asset
associ differenti test platform
primari moat sourc along switch cost
divis agil tool primarili help clinician
diagnos develop therapeut plan patient
concentr oncolog indic
acquisit dako agil enjoy top-tier posit
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
market see potenti disrupt clinic
diagnost market agil must reli heavili
innov succeed creat uncertainti
around sustain return busi
long run point though think agil
innov chop enough
focu workflow
capabl instrument autom regulatori matter
compet effect market long run
therefor see segment drag agil
moat trend current despit higher potenti disrupt
risk long run
anatom patholog market tissue-bas cancer
diagnost make major player top-tier diagnost
firm roch compani
instrument base busi relat consum
sale make attract specialti segment
sophist
time-consum test rel broader diagnost
market agil also oper companion diagnost
tool market make consum test help
physician tailor therapeut option patient
provid sampl prepar tool import next
gener sequenc market overal think
divis strong growth prospect combin intang
asset switch cost associ larg
agil sustain
agil moat trend appear stabl us intang
asset front compani continu innov improv
perform analyt tool well user
interfac innov help agil least
maintain market share initi project decis
made crucial on-going system placement
continu relev industri life scienc
appli market includ relat servic
consum sale also see limit
disrupt risk given regulatori reproduc
train factor creat signific barrier entri
sticki busi overal expect limit
group competitor includ perkin elmer
shimadzu thermo fisher ration
chang substanti go forward rel
matur sticki end market see potenti
challeng ahead agil clinic diagnost segment
around sale pit larg foe
roch one end spectrum
innov new entrant end fragment
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
oagil innov engin cost control effort
display strong growth
margin expans sinc spin electron
measur busi keysight novemb
well-establish leader mani core
familiar agil instrument servic
make market share gain competitor difficult
concern
oagil continu increas exposur sticki
acquisit emerg cell analysi field
odu depend one-tim sale
exposur cyclic end market agil
financi result may weaken uncertain time
ochines govern initi particularli
food market constrain growth key countri
fiscal initi may affect demand
agil tool near long term
oagil increas appetit acquisit add
uncertainti around magnitud
econom profit long run
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
agil balanc sheet remain strong even recent
debt-fund acquisit end octob agil
held billion cash compar billion debt
gross leverag around time biotek
acquisit complet august
futur expect agil access extern financ
boost return sharehold includ repurchas
billion avail share repurchas
author octob make acquisit
refin outstand debt agil debt matur
includ million short-term debt billion
senior unsecur note princip million due
million due million due
million due howev expect firm
remain rel conserv balanc sheet
given histor preced cyclic end
give agil medium uncertainti rate thank
sticki end market result rel steadi
demand trend despit depend one-tim
instrument sale delay weak time
gener economi specif end market
half agil busi recur natur
mean half particular experi volatil
due macroeconom condit budget constraint
exampl agil chemic energi end market
suffer oil ga price plummet
weak condit agil client delay capit
spend cut agil result end market
fortun agil divers custom base off-set
pressur although firm overal growth
deceler rebound recent year along
stronger demand trend chemic energi
must innov remain relev end user
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
establish competitor new entrant introduc better
product develop stronger relationship custom
agil may lose market share well abil extract
price increas futur factor could cut
growth margin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
repres date owner name posit common share held report holder issuer
share
fund
share
fund
assign agil exemplari mark stewardship unlik
aggress consolid industri
appreci agil select use acquisit
divestitur recent biotek acquisit cell
analysi keysight technolog spin-off
novemb improv asset product build
capabl new market although one could argu
valuat paid somewhat rich highli
select rel aggress peer
help agil consist deliv attract return
invest capit also maintain healthi balanc
sharehold modest dividend opportunist
share repurchas program gener view
appropri given potenti cyclic end
market overal
compens polici align
sharehold perform metric determin
variabl compens contribut
ceo pay fiscal name execut
share stock perform rel peer group
compani
spin-off keysight technolog mike
mcmullen previous presid
chemic analysi segment replac william sullivan
ceo agil earli mcmullen long histori
compani predecessor hewlett-packard
date back think transit top
manag team smooth especi
appreci manag abil consist meet
exceed guidanc sinc spin-off
help strong end market period
firm innov cost control effort mcmullen
also possess one seat agil board
director koh boon hwee -- privat equiti investor
agil board member sinc former hewlett
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
packard execut respons primarili asia
pacif region -- serv chairman board sinc
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
agil mere first-quart expect due
wide-moat turn solid fiscal first-
quarter result met cap iq consensu revenu
ep perspect despit weak china relat
coronaviru highlight past
manag typic give conserv guidanc
abl keep outlook intact although
coronaviru outbreak materi affect result
manag typic conserv guidanc look
realist usual due event
consensu expect may need declin bit
coronaviru
quarter agil gener billion sale
china specif
manag highlight compani trend
ahead expect extend lunar new year
holiday lost million sale late
end market above-compani growth gener
biopharmaceut core growth diagnost
environmental/forens biopharmaceut end
market investor know agil grew
basi point higher chief rival top
line also compani averag food
end market actual acceler declin
fiscal manag maintain revenu rang
billion core growth
adjust earn per share guidanc
expect first second quarter
keep expect slightli
manag outlook would note capit
alloc activ like share repurchas gener
conservat may keep manag outlook
view near futur howev admit prolong
weak china could make manag outlook
appear realist normal
agil beat consensu fourth quarter guid
conserv chang valuat expect
wide-moat agil technolog turn solid fiscal
fourth-quart result beat capiq consensu
revenu earn per share perspect howev free
cash flow key determin fair valu
estim fell expect look
like remain weak manag continu
trend conserv revenu earn per share
guidanc expect given
compani penchant beat conserv
guidanc may alter revenu earn
expect materi dig result
first glanc expect make signific
chang fair valu estim
quarter agil gener billion sale
core growth year year consensu
billion compani highlight strength widest-moat
segment serv biopharmaceut firm
quarter sale grew tough compar
agil appear differenti key peer
water grew end market
third quarter small-molecul custom delay
capit equip order agil appear suffer
similar weak end market also
show on-going strength large-molecul end market
particularli oligonucleotid offer
increasingli use new drug develop
manufactur process manag highlight
agil gener revenu new oligonucleotid
manufactur facil colorado first time
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
quarter key site help meet demand
fast-grow space
compani also highlight momentum instrument
portfolio manag said call exist
product portfolio never stronger compani
new product pipelin also remain full accord
given strong product line-up pipelin
slightli disappoint compani outlook fiscal
expect howev manag
tendenc give conserv guidanc
dig may significantli chang revenu
earn per share expect year
free cash flow perspect though plan cut
estim base expect tax outflow relat
recent acquir intang asset million
signific chang firm gener
million free cash flow fiscal manag
current expect roughli million free cash flow
fiscal significantli previou expect
billion manag revenu rang fiscal
billion core growth includ
recent biotek acquisit previou forecast
billion adjust earn per share
guidanc growth also slightli
forecast may make tweak
estim plan cut revenu
earn per share estim manag
rang see latter slightli conserv given
current busi trend potenti capital-alloc
activ fulli incorpor bottom-lin
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end octob
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end octob
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
